Reply: To PMID 25440819.

R. Ghandour,J. McKiernan

DOI: https://doi.org/10.1016/j.urology.2014.07.074

IF: 2.633

Urology

Abstract:

What problem does this paper attempt to address?

Fluctuations of Northeast Arctic Cod Catches: A Review of Possible Sources

O. Nakken

DOI: https://doi.org/10.4027/RGSFCC.2008.02

Abstract:Many stocks of Atlantic cod (Gadus morhua) on both sides of the North Atlantic are currently at much reduced levels of biomass, but this situation is not in all instances the result of long, continuous decline. Most Northwest Atlantic stocks declined to low levels during the 1970s, but increased during the 1980s before declining even more severely during the late 1980s and early 1990s. Several of these stocks have shown little recovery despite severe restrictions on directed fishing. Many stocks in the Northeast Atlantic have experienced sustained increases and sustained decreases, but generally not in concert. Among-stock comparisons illustrate that fishing has played a dominant role in the dynamics of all cod stocks, but variability in climate has contributed to variability in recruitment, individual growth, and natural mortality. A cooling event during the last three decades of the twentieth century contributed to the rapid decline of several stocks in the Northwest Atlantic, and changes in life-history traits (growth rate, age and size at maturity) and in the biotic environment (predators and prey) may be contributing to recovery being slow.
Psychiatric adverse events following COVID-19 vaccination: a population-based cohort study in Seoul, South Korea

Hong Jin Kim,Min-Ho Kim,Myeong Geun Choi,Eun Mi Chun

DOI: https://doi.org/10.1038/s41380-024-02627-0

IF: 11

2024-06-04

Molecular Psychiatry

Abstract:Evidence has suggested an increased risk of psychiatric manifestations following viral infections including coronavirus disease-2019 (COVID-19). However, psychiatric adverse events (AEs) after COVID-19 vaccination, which were documented in case reports and case series, remain unclear. This study is aimed to investigate the psychiatric AEs after COVID-19 vaccination from a large population-based cohort in Seoul, South Korea. We recruited 50% of the Seoul-resident population randomly selected from the Korean National Health Insurance Service (KNHIS) claims database on 1, January, 2021. The included participants ( n = 2,027,353) from the Korean National Health Insurance Service claims database were divided into two groups according to COVID-19 vaccination. The cumulative incidences per 10,000 of psychiatric AEs were assessed on one week, two weeks, one month, and three months after COVID-19 vaccination. Hazard ratios (HRs) and 95% Confidence interval (CIs) of psychiatric AEs were measured for the vaccinated population. The cumulative incidence of depression, anxiety, dissociative, stress-related, and somatoform disorders, sleep disorders, and sexual disorders at three months following COVID-19 vaccination were higher in the vaccination group than no vaccination group. However, schizophrenia and bipolar disorders showed lower cumulative incidence in the vaccination group than in the non-vaccinated group. Depression (HR [95% CI] = 1.683 [1.520–1.863]), anxiety, dissociative, stress-related, and somatoform disorders (HR [95% CI] = 1.439 [1.322–1.568]), and sleep disorders (HR [95% CI] = 1.934 [1.738–2.152]) showed increased risks after COVID-19 vaccination, whereas the risks of schizophrenia (HR [95% CI] = 0.231 [0.164–0.326]) and bipolar disorder (HR [95% CI] = 0.672 [0.470–0.962]). COVID-19 vaccination increased the risks of depression, anxiety, dissociative, stress-related, and somatoform disorders, and sleep disorders while reducing the risk of schizophrenia and bipolar disorder. Therefore, special cautions are necessary for administering additional COVID-19 vaccinations to populations vulnerable to psychiatric AEs.

biochemistry & molecular biology,neurosciences,psychiatry
Cardiac and Neurological Complications Post COVID-19 Vaccination: A Systematic Review of Case Reports and Case Series

Kai Wei Lee,Sook Fan Yap,Syafinaz Amin-Nordin,Yun Fong Ngeow

DOI: https://doi.org/10.3390/vaccines12060575

2024-05-25

Vaccines

Abstract:Following mass vaccinations for the control of the COVID-19 epidemic, a spectrum of cardiac and neurological disorders was reported among vaccinated individuals. This study examined the range of complications documented and factors related to their occurrence. Three electronic databases were searched for case reports and case series with descriptions of cardiac and/or neurological complications in COVID-19 vaccine recipients. A total of 698 vaccinees were included in this review, of which 259 (37.1%) had cardiac and 439 (62.9%) had neurological complications. Inflammatory conditions were the commonest among the cardiac complications; while polyneuropathy, demyelinating diseases and cerebrovascular disorders were the more common neurological complications. The mean age of those with cardiac complications (33.8 years) was much younger than those with neurological complications (49.7 years). There was no notable difference in the gender distribution between these two groups of vaccine recipients. mRNA vaccines (all brands) were associated with almost 90.0% of the cardiac complications, whereas viral vector vaccines were associated with slightly over half (52.6%) of the neurological complications. With regard to the dose, cardiac complications were more common after the second (69.1%), whereas neurological complications were more common after the first dose (63.6%). The majority of the cases had an uncomplicated clinical course. Nevertheless, 5.9% of cases with neurological complications and 2.5% of those with cardiac complications were fatal, underscoring the significance of the consistent surveillance and vigilant monitoring of vaccinated individuals to mitigate these occurrences.

immunology,medicine, research & experimental
Broad-spectrum of non-serious adverse events following COVID-19 vaccination: A population-based cohort study in Seoul, South Korea

Jee Hyun Suh,Hong Jin Kim,Min-Ho Kim,Myeong Geun Choi,Eun Mi Chun

DOI: https://doi.org/10.1101/2023.11.15.23298566

2024-03-07

Abstract:Much of the current literature on the adverse effects occurring after the coronavirus disease-2019 (COVID-19) vaccination focused on serious adverse events (AEs). Consequently, the non-serious AEs have yet to be comprehensively elucidated. This study aims to investigate the incidence rate and risk of non-serious AEs including gynecological, hematological, dermatological, ophthalmological, otologic, and dental problems following the COVID-19 vaccination. We conducted a population-based cohort study was conducted with the National Health Insurance Service (NHIS) database in Seoul, South Korea. The cumulative incidence rate (cIR) per 10,000 population, Odds ratio, and Hazard ratio (HR) with a 95% Confidence Interval (CI) were measured to assess the non-serious AEs, as reported by the Vaccine Adverse Event Reporting Center, after COVID-19 vaccination. The cIR of non-serious AEs for three months was significantly higher in vaccinated subjects than in non-vaccinated subjects, except for endometriosis. The vaccination significantly increased the risks of all the non-serious AEs except for visual impairment. The risk of inner ear disease showed the highest HRs (HR [95% CI] = 2.37 [2.15-2.60]) among the non-serious AEs following COVID-19 vaccination. Among the vaccinated subjects, heterologous vaccination was associated with the increased risk of most of the non-serious AEs. The three-month risks of incidental non-serious AEs are substantially higher in the COVID-19 vaccinated subjects than in non-vaccinated controls. Our findings suggested that vaccinated subjects with predisposition are potentially vulnerable to the occurrence of broad-spectrum AEs although the COVID-19 vaccines may not be serious.

Infectious Diseases (except HIV/AIDS)
Global and regional burden of vaccine‐associated facial paralysis, 1967–2023: Findings from the WHO international pharmacovigilance database

Yi Deun Jeong,Kyeongmin Lee,Sooji Lee,Jaeyu Park,Hyeon Jin Kim,Jinseok Lee,Jiseung Kang,Louis Jacob,Lee Smith,Masoud Rahmati,Guillermo F. López Sánchez,Elena Dragioti,Yejun Son,Soeun Kim,Seung Geun Yeo,Hayeon Lee,Dong Keon Yon

DOI: https://doi.org/10.1002/jmv.29682

IF: 20.693

2024-05-26

Journal of Medical Virology

Abstract:The scarce and conflicting data on vaccine‐associated facial paralysis limit our understanding of vaccine safety on a global scale. Therefore, this study aims to evaluate the global burden of vaccine‐associated facial paralysis and to identify the extent of its association with individual vaccines, thereby contributing to the development of a more effective vaccination program. We used data on vaccine‐associated facial paralysis from 1967 to 2023 (total reports, n = 131 255 418 418) from the World Health Organization International Pharmacovigilance Database. Global reporting counts, reported odds ratios (ROR), and information components (ICs) were computed to elucidate the association between the 16 vaccines and the occurrence of vaccine‐associated facial paralysis across 156 countries. We identified 26 197 reports (men, n = 10 507 [40.11%]) of vaccine‐associated facial paralysis from 49 537 reports of all‐cause facial paralysis. Vaccine‐associated facial paralysis has been consistently reported; however, a pronounced increase in reported incidence has emerged after the onset of the coronavirus disease 2019 (COVID‐19) pandemic, which is attributable to the COVID‐19 mRNA vaccine. Most vaccines were associated with facial paralysis, with differing levels of association, except for tuberculosis vaccines. COVID‐19 mRNA vaccines had the highest association with facial paralysis reports (ROR, 28.31 [95% confidence interval, 27.60–29.03]; IC, 3.37 [IC0.25, 3.35]), followed by encephalitis, influenza, hepatitis A, papillomavirus, hepatitis B, typhoid, varicella‐zoster, meningococcal, Ad‐5 vectored COVID‐19, measles, mumps and rubella, diphtheria, tetanus toxoids, pertussis, polio, and Hemophilus influenza type b, pneumococcal, rotavirus diarrhea, and inactivated whole‐virus COVID‐19 vaccines. Concerning age‐ and sex‐specific risks, vaccine‐associated facial paralysis was more strongly associated with older age groups and males. The serious adverse outcome and death rate of vaccine‐associated facial paralysis were extremely low (0.07% and 0.00%, respectively). An increase in vaccine‐induced facial paralysis, primarily owing to COVID‐19 mRNA vaccines, was observed with most vaccines, except tuberculosis vaccines. Given the higher association observed in the older and male groups with vaccine‐associated facial paralysis, close monitoring of these demographics when administering vaccines that are significantly associated with adverse reactions is crucial.

virology
Risk of encephalitis and meningitis after COVID-19 vaccination in South Korea: a self-controlled case series analysis

Ju Hwan Kim,Dongwon Yoon,Hwa Yeon Ko,Kyungyeon Jung,Jun-Sang Sunwoo,Won Chul Shin,Jung-Ick Byun,Ju-Young Shin

DOI: https://doi.org/10.1186/s12916-024-03347-6

IF: 9.3

2024-03-16

BMC Medicine

Abstract:Several neurological manifestations shortly after a receipt of coronavirus infectious disease 2019 (COVID-19) vaccine have been described in the recent case reports. Among those, we sought to evaluate the risk of encephalitis and meningitis after COVID-19 vaccination in the entire South Korean population.

medicine, general & internal
COVID-19 vaccination and ocular adverse events: a self-controlled case series study from the entire South Korean population

Sungsoon Hwang,Se Woong Kang,Jaehwan Choi,Kyung-Ah Park,Dong Hui Lim,Ju-Young Shin,Danbee Kang,Juhee Cho,Sang Jin Kim

DOI: https://doi.org/10.1016/j.ajo.2024.08.015

2024-08-21

Abstract:Purpose: This study aimed to assess the risk of ocular adverse events, including retinal artery occlusion (RAO), retinal vein occlusion (RVO), non-infectious uveitis (NIU), non-infectious scleritis (NIS), optic neuritis (ON), ischemic optic neuropathy (ION), and ocular motor cranial nerve palsy (OMCNP), following coronavirus disease 2019 (COVID-19) vaccination. Design: Population-based self-controlled case series METHODS: This study utilized nationwide claims and vaccination data provided by the Korea National Health Insurance Service and Korea Disease Control and Prevention Agency. From the entire South Korean population of 52 million individuals, patients with incident RAO, RVO, anterior NIU, non-anterior NIU, NIS, ON, ION, or OMCNP between January 2021 and March 2022 were included. The post-vaccination risk period was defined as up to 56 days after COVID-19 vaccination. The relative incidence rate ratios (IRRs) for RAO, RVO, anterior NIU, non-anterior NIU, NIS, ON, ION, and OMCNP during the risk periods were measured using conditional Poisson regression. Results: The study included 6,590, 70,120, 137,958, 17,921, 15,492, 2,039, 49,089, and 11,312 cases of incident RAO, RVO, anterior NIU, non-anterior NIU, NIS, ON, ION, and OMCNP, respectively. The IRRs (95% confidence interval) during the early risk period (0-28 days) were 0.95 (0.88-1.01), 0.96 (0.94-0.98), 0.93 (0.91-0.94), 0.93 (0.89-0.96), 0.96 (0.92-1.01), 1.04 (0.92-1.18), 0.98 (0.95-1.00), and 0.91 (0.86-0.96), respectively. In the late risk period (29-56 days), the IRRs were 0.96 (0.89-1.03), 0.93 (0.91-0.96), 0.96 (0.95-0.98), 1.00 (0.95-1.04), 0.96 (0.91-1.01), 1.00 (0.87-1.15), 1.01 (0.98-1.04), and 0.95 (0.90-1.01), respectively. Conclusion: COVID-19 vaccination did not increase the risk of incident RAO, RVO, anterior NIU, non-anterior NIU, NIS, ON, ION, or OMCNP during the post-vaccination period.
Neonatal congestive heart failure as the presenting symptom of cerebral arteriovenous malformation.

C. Carroll,R. Jakoby

DOI: https://doi.org/10.3171/JNS.1966.25.2.0159

IF: 5.408

1966-08-01

Journal of Neurosurgery

Abstract:THOUGH peripheral fistulas between major vessels elsewhere in the body may give rise to cardiac enlargement 6,3~ and cardiac failure, s~ it has been generally assumed tha t even large arteriovenous malformations of the brain do not result in congestive heart failure. I t was therefore surprising to be consulted with regard to a newborn girl in congestive heart failure, the basis of which was thought to be a cerebral arteriovenous malformation as deduced from studies of oxygen concentrat ion obtained during hear~ catheterization. We verified the diagnosis of arteriovenous malformation by cerebral angiography and believe that this lesion was the cause of the cardiac failure. Curiously, when Steinheil first described an arteriovenous malformation, he noted eardiomegaly. 37 However, in a review of several large series, 1,23,2s,4~ a total of 919 patients, no cardiac symptoms were noted, while one series 2s described cardiomegaly in 9 of 110 cases. The relationship between cerebral arteriovenous malformation and the cardiovascular system was a t tacked more directly by H55k et al. 16 who evaluated 13 such patients from this point of view. In no case were symptoms present to indicate an increased load on the heart or the circulation. The histories of an additional 1~3 patients were analyzed, again without demonstration of cardiovascular symptoms. I t is pertinent tha t the youngest pa t ient in tha t report 16 was 14 years old and, indeed, the calculation has been made tha t only 35% of arteriovenous malformations become symptomat ic before the age of 20.17 In a series dealing with 11 children between 4 and 15 years of age, there was no evidence for congestive heart failure accompanying such a cerebral lesion.27 A search of the li terature reveals 11 other patients who had a cerebral arteriovenous malformation associated with signs of con-
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection

Martina Patone,Lahiru Handunnetthi,Defne Saatci,Jiafeng Pan,Srinivasa Vittal Katikireddi,Saif Razvi,David Hunt,Xue W. Mei,Sharon Dixon,Francesco Zaccardi,Kamlesh Khunti,Peter Watkinson,Carol A. C. Coupland,James Doidge,David A. Harrison,Rommel Ravanan,Aziz Sheikh,Chris Robertson,Julia Hippisley-Cox

DOI: https://doi.org/10.1038/s41591-021-01556-7

IF: 82.9

2021-10-25

Nature Medicine

Abstract:Abstract Emerging reports of rare neurological complications associated with COVID-19 infection and vaccinations are leading to regulatory, clinical and public health concerns. We undertook a self-controlled case series study to investigate hospital admissions from neurological complications in the 28 days after a first dose of ChAdOx1nCoV-19 ( n = 20,417,752) or BNT162b2 ( n = 12,134,782), and after a SARS-CoV-2-positive test ( n = 2,005,280). There was an increased risk of Guillain–Barré syndrome (incidence rate ratio (IRR), 2.90; 95% confidence interval (CI): 2.15–3.92 at 15–21 days after vaccination) and Bell’s palsy (IRR, 1.29; 95% CI: 1.08–1.56 at 15–21 days) with ChAdOx1nCoV-19. There was an increased risk of hemorrhagic stroke (IRR, 1.38; 95% CI: 1.12–1.71 at 15–21 days) with BNT162b2. An independent Scottish cohort provided further support for the association between ChAdOx1nCoV and Guillain–Barré syndrome (IRR, 2.32; 95% CI: 1.08–5.02 at 1–28 days). There was a substantially higher risk of all neurological outcomes in the 28 days after a positive SARS-CoV-2 test including Guillain–Barré syndrome (IRR, 5.25; 95% CI: 3.00–9.18). Overall, we estimated 38 excess cases of Guillain–Barré syndrome per 10 million people receiving ChAdOx1nCoV-19 and 145 excess cases per 10 million people after a positive SARS-CoV-2 test. In summary, although we find an increased risk of neurological complications in those who received COVID-19 vaccines, the risk of these complications is greater following a positive SARS-CoV-2 test.

biochemistry & molecular biology,cell biology,medicine, research & experimental
COVID-19 vaccine safety: Background incidence rates of anaphylaxis, myocarditis, pericarditis, Guillain-Barré Syndrome, and mortality in South Korea using a nationwide population-based cohort study

Hye Su Jeong,Byung Chul Chun

DOI: https://doi.org/10.1371/journal.pone.0297902

IF: 3.7

2024-02-22

PLoS ONE

Abstract:To properly assess an association between vaccines and specific adverse events requires a comparison between the observed and background rates; however, studies in South Korea are currently limited. Therefore, in this study, we estimated the background incidence of anaphylaxis, myocarditis, pericarditis, Guillain-Barré syndrome (GBS), and mortality in South Korea. A retrospective cohort study was conducted using the National Sample Cohort (NSC) data. Using NSC, the background incidence rate was estimated by dividing the number of episodes during 2009–2019 by the total population by year and then multiplying by 100,000. Using Statistics Korea data, the background mortality rate was estimated by dividing the number of deaths, during 2009–2019 by the standard population for that year and then multiplying by 100,000. Using background mortality rates, we predicted mortality rates for 2021 using autoregressive integrated moving average models. Further, the expected mortality rates were compared with observed mortality rates. The age-adjusted incidence rate (AIR) of anaphylaxis increased from 4.28 to 22.90 cases per 100,000 population (p = 0.003); myocarditis showed no significant increase, changing from 0.56 to 1.26 cases per 100,000 population (p = 0.276); pericarditis increased from 0.94 to 1.88 cases per 100,000 population (p = 0.005); and GBS increased from 0.78 to 1.21 cases per 100,000 population (p = 0.013). The age-adjusted mortality rate decreased from 645.24 to 475.70 deaths per 100,000 population (p <0.001). The 2021 observed/expected mortality rates for overall (ratio: 1.08, 95% confidence interval [CI]: 1.07–1.08), men (ratio: 1.07, 95% CI: 1.07–1.08), and women (ratio: 1.08, 95% CI: 1.07–1.09), were all significantly higher. When stratified by age group, those aged ≥80 (ratio: 1.16, 95% CI: 1.15–1.17), 60–69 (ratio: 1.11, 95% CI: 1.10–1.13), and 20–29 years old (ratio: 1.07, 95% CI: 1.02–1.13) were also significantly higher. Through the estimation of background rates related to anaphylaxis, myocarditis, pericarditis, GBS, and mortality, we established a reference point for evaluating the potential excess occurrence of adverse events following COVID-19 vaccination. This reference point serves as substantive evidence supporting the safety profile of COVID-19 vaccines.

multidisciplinary sciences
Headache Triggered by Coronavirus Disease 2019 Vaccination Increases in Line with History of Allergic Disorders and Comorbidities Like Depression and Fibromyalgia: An Analysis of the US Vaccine Adverse Event Reporting System

Gülcan Göçmez Yilmaz,Nazlican Murzakhanov,Didem Derici Yildirim,Betül Baykan,David Garcia-Azorin,Jennifer A. Frontera,Andrea Sylvia Winkler,Aynur Özge

DOI: https://doi.org/10.4103/nsn.nsn_84_23

2023-12-31

Neurological Sciences and Neurophysiology

Abstract:The coronavirus disease 2019 (COVID-19) pandemic was officially declared by the World Health Organization in March 2020 and has become a significant health concern. [ 1 , 2 ] Consequently, studies on vaccines commenced right after the outbreak, resulting in the development of more than 70 SARS-COV-2 vaccines with different vaccine technologies. [ 3 ] In December 2020, the Food and Drug Administration (FDA) granted Emergency Use Authorization to Pfizer-BioNTech and Moderna mRNA vaccines for the first time. [ 4 ]

neurosciences
Central Nervous System Demyelination Following COVID-19 mRNA-Based Vaccination: Two Case Reports and Literature Review

Shirley Lee,Jyh Yung Hor,Kee Leong Koh,Yuen Kang Chia

DOI: https://doi.org/10.1177/11795735221102747

2022-05-24

Abstract:As the world embarks on mass vaccination against SARS-CoV2 to alleviate the spread of this highly contagious novel coronavirus, there are growing anecdotal reports on immune-related neurological complications following immunisation. Similarly, we encountered 2 cases of central nervous system demyelination at our centre with Comirnaty (BNT162b2), a mRNA-based COVID-19 vaccine. Our first patient had typical clinical-radiological manifestations of acute disseminated encephalomyelitis (ADEM) after his COVID-19 vaccination. This was the sixth reported case to date. Our second patient presented with an unusual complaint of trigeminal neuralgia, with an identifiable demyelinating lesion observed in the pons on neuroimaging. Both cases responded well to immunotherapy. However, larger prospective controlled studies and formal registries are much needed to ascertain a possible relationship between COVID-19 vaccines and acute central nervous system demyelination.
Neurological Events Following COVID-19 Vaccination: Does Ethnicity Matter?

Manav V. Vyas,Robert Chen,Michael A. Campitelli,Tomi Odugbemi,Isobel Sharpe,Joseph Y. Chu

DOI: https://doi.org/10.1017/cjn.2024.299

2024-10-05

Abstract:We conducted a retrospective cohort study in Ontario, Canada between December 1, 2020 and June 31, 2021 to compare the incidence of neurological events (hospitalization or emergency room visit) within six weeks of COVID-19 vaccination in Chinese, South Asian and Other ethnic groups. Compared to Others, the crude rates after the first dose for Bell's palsy, ischemic stroke and intracerebral hemorrhage were lower in Chinese (34, 159 and 48 per 1,000,000 doses) and in South Asians (44, 148 and 32), but similar after adjusting for age, sex and vaccine type. Our findings should help encourage vaccination for all, irrespective of ethnicity.
Retinal Vascular Occlusions After COVID-19 Vaccination in South Korea: A Nation-Wide Population-Based Study

Yeji Kim,Kyungdo Han,Jae Hui Kim

DOI: https://doi.org/10.1080/09286586.2024.2399345

2024-09-19

Ophthalmic Epidemiology

Abstract:Purpose To investigate the association between the retinal vascular occlusion and vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

ophthalmology
A further complication of informed consent.

L. Arnold

DOI: https://doi.org/10.2307/3563447

1987-12-01

The Hastings Center Report

Abstract:
Increased risk of functional neurological disorders following SARS‐CoV‐2 vaccination

Andrea Pilotto,Marcello Catania,Irene Mattioli,Nicola Zoppi,Giulia Ceccardi,Renata Rao,Stefano Gipponi,Mauro Magoni,Massimo Gamba,Alessandro Padovani

DOI: https://doi.org/10.1111/ene.16191

2024-01-03

European Journal of Neurology

Abstract:Background and purpose The purpose of this study was to evaluate the possible correlation between SARS‐CoV‐2 vaccines and the onset of neurological syndromes. The aim was to challenge the association between SARS‐CoV‐2 vaccinations and the onset of acute functional neurological disorders (FNDs) compared to other neurological syndromes in hospitalized patients. Methods In this prospective cohort study, all adult inpatients consecutively admitted to a tertiary neurological centre were included. The prevalence and characteristics of neurological syndromes were compared between unvaccinated and vaccinated cases stratified according to the onset from vaccination. The study involved 843 subjects, namely 411 unvaccinated (UVC) and 432 vaccinated cases; these groups were comparable for demographics and clinical diagnosis distribution. Results Compared to UVC, subjects hospitalized within the first 30 days from vaccine exhibited higher prevalence of FNDs (12.3% vs. 3.6%; odds ratio 4.2, 95% confidence interval 1.6–11.1) and headache (10.8% vs. 5%; odds ratio 4.1, 95% confidence interval 1.9–8.8) but no other neurological syndromes. The FND cases following vaccinations showed similar premorbid conditions and severity but a higher percentage of sensory symptoms and pain compared to UVC FND cases. Conclusions SARS‐CoV‐2 vaccination is associated with a significant short‐term increased risk of FND and headache requiring hospitalization in an acute neurological setting.

neurosciences,clinical neurology
Thromboembolism after coronavirus disease 2019 vaccination in atrial fibrillation/flutter: a self-controlled case series study

You-Jung Choi,Jaehyun Lim,Sungho Bea,Jieun Lee,Jah Yeon Choi,Seung Young Rho,Dae-In Lee,Jin Oh Na,Hyung-Kwan Kim

DOI: https://doi.org/10.1093/eurheartj/ehae335

IF: 39.3

2024-07-13

European Heart Journal

Abstract:Concerns about the safety of coronavirus disease 2019 (COVID-19) vaccines in patients with atrial fibrillation/flutter (AF/AFL) have arisen due to reports of thrombo-embolic events following COVID-19 vaccination in the general population. This study aimed to evaluate the risk of thrombo-embolic events after COVID-19 vaccination in patients with AF/AFL. This was a modified self-controlled case-series study using a comprehensive nationwide-linked database provided by the National Health Insurance Service in South Korea to calculate incidence rate ratios (IRRs) of thrombo-embolic events. The study population included individuals aged ≥12 years who were either vaccinated (e.g. one or two doses) or unvaccinated during the period from February to December 2021. The primary outcome was a composite of thrombo-embolic events, including ischaemic stroke, transient ischaemic attack, and systemic thromboembolism. The risk period was defined as 0–21 days following COVID-19 vaccination. The final analysis included 124 127 individuals with AF/AFL. The IRR of thrombo-embolic events within 21 days after COVID-19 vaccination, compared with that during the unexposed control period, was 0.93 [95% confidence interval (CI) 0.77–1.12]. No significant risk variations were noted by sex, age, or vaccine type. However, patients without anticoagulant therapy had an IRR of 1.88 (95% CI 1.39–2.54) following vaccination. In patients with AF/AFL, COVID-19 vaccination was generally not associated with an increased risk of thrombo-embolic events. However, careful individual risk assessment is required when advising vaccination for those not on oral anticoagulant, as these patients exhibited an increased risk of thrombo-embolic events post-vaccination. Summary of the study population, methods, and main findings. AF, atrial fibrillation; AFL, atrial flutter; K-COV-N, Korea Disease Control and Prevention Agency–COVID-19–National Health Insurance Service; CI, confidence interval; COVID-19, coronavirus disease 2019; IRR, incidence rate ratio

cardiac & cardiovascular systems
Incidence and clinical characteristics of adverse neurological events and stroke-like syndrome associated with immune stress-related response after COVID-19 vaccination in 2021 from Thailand

Wikawee Sirisuk,Wasithep Limvorapitak,Praween Lolekha,Kanthida Methaset,Kongkiat Kulkantrakorn

DOI: https://doi.org/10.1016/j.clineuro.2023.107804

2023-05-31

Clinical Nephrology - Case Studies

Abstract:Highlights • Adverse events following immunizations (AEFIs) after COVID-19 vaccination which are similar to stroke symptoms may affect the vaccine roll-out campaign to prevent the coronavirus 2019 outbreak. • The incidence of neurological AEFIs after COVID-19 vaccination was much higher among recipients of ChAdOx-1 nCoV-19 vaccine than inactivated vaccine and mRNA vaccine. • Most neurological AEFIs were immunization stress-related response (ISRR). • Stroke-like symptoms are not common complaint in patients with ISRR and could aid in the differential diagnosis from minor stroke patients. Objectives AEFIs (adverse events following immunizations), especially ISRR ( immune stress related response) which can cause stroke-like symptoms may affect the vaccine roll-out campaign to prevent the coronavirus 2019 outbreak. Methods This study aimed to describe the incidence and clinical characteristics of neurological AEFIs and stroke-like symptoms associated with ISRR after COVID-19 vaccination. Characteristics of ISRR were compared to minor ischemic stroke patients during the same period of the study. During March to September 2021, we retrospectively collected data of participants aged ≥ 18 years who received COVID-19 vaccine and developed AEFIs from Thammasat university vaccination center (TUVC). Data of neurological AEFIs patients and minor ischemic stroke patients were collected from hospital electronic medical record system. Results COVID-19 vaccine were administered at TUVC for 245,799 doses. AEFIs were reported in 129,652 instances (52.6%). ChADOx-1 nCoV-19 viral vector vaccine has the most frequent occurrence of AEFIs (58.0%), and neurological AEFIs (12.6%). 83% of neurological AEFI was headache. Most were mild and did not need medical attention. Of 119 patients who received COVID-19 vaccine from anywhere with neurological AEFIs and presented to TUH, ISRR was diagnosed in 107 patients (89.9%) and all patients who has follow-up data (30.8%) showed clinical improvement. In comparison with minor ischemic stroke (116 patients), ISRR patients had significantly less ataxia, facial weakness, weakness of arm/leg and speech disturbances (P < 0.001). Conclusion The incidence of neurological AEFIs after COVID-19 vaccination was higher among recipients of ChAdOx-1 nCoV-19 vaccine (12.6%) than inactivated vaccine (6.2%) and mRNA vaccine (7.5%). However, most neurological AEFIs were ISRR, had mild severity and resolved within 30 days. Stroke-like symptoms occurred less frequently than patients with minor ischemic stroke.
Vaccination and the risk of post-acute sequelae after COVID-19 In the Omicron-predominant period

Kyungmin Huh,Young-Eun Kim,Gi Hwan Bae,Jong Youn Moon,Ji-Man Kang,Jacob Lee,Jang-Whan Bae,Kyong Ran Peck,Jaehun Jung

DOI: https://doi.org/10.1016/j.cmi.2024.01.028

IF: 13.31

2024-02-08

Clinical Microbiology and Infection

Abstract:Objectives To assess the association of primary and third doses of vaccination with the risk of post-acute sequelae of COVID-19. Methods This retrospective cohort study utilized a combined database of nationwide healthcare claims data, COVID-19 patient registry, and vaccination records from South Korea. Individuals diagnosed with COVID-19 in the Omicron variant-dominant period of January to March 2022 were tracked for 30–120 days post-infection. The exposure of interest was the receipt of primary and third doses of the SARS-CoV-2 vaccine. The occurrence of 26 specific conditions in eight domains was compared using Cox regression with inverse probability of treatment weighting. Results This study included 394,773 unvaccinated individuals and 7,604,081 individuals receiving ≥2 doses of vaccine. Compared with unvaccinated individuals, vaccination with at least two doses was associated with a reduced risk (adjusted hazard ratio; 95% confidence interval) of several conditions, including ischemic heart disease (0.73; 0.57–0.94), heart failure (0.55; 0.48–0.63), cardiac dysrhythmia (0.72; 0.61–0.85), cardiac arrest (0.41; 0.33–0.51), pulmonary embolism (0.66; 0.52–0.84), venous thromboembolism (0.54; 0.44–0.66), acute renal failure (0.56; 0.46–0.67), new dialysis (0.45; 0.34–0.59), chronic obstructive pulmonary disease (0.74; 0.65–0.84), acute pancreatitis (0.64; 0.51–0.80), and diabetes (0.82; 0.71–0.95). The risks of heart failure, cardiac dysrhythmias, cardiac arrest, pulmonary embolism, and new dialysis were lower in those vaccinated with three doses compared with two doses. Conclusions Vaccination was associated with a decreased risk of post-acute sequelae of COVID-19, suggesting its potential role in mitigating the indirect impacts of COVID-19.

infectious diseases,microbiology
Guillain-Barré Syndrome and Variants Following COVID-19 Vaccination: Report of 13 Cases

Jee-Eun Kim,Young Gi Min,Je-Young Shin,Young Nam Kwon,Jong Seok Bae,Jung-Joon Sung,Yoon-Ho Hong

DOI: https://doi.org/10.3389/fneur.2021.820723

2022-01-27

Abstract:Background: Amidst growing concern about an increased risk of Guillain-Barré syndrome (GBS) following COVID-19 vaccination, clinical and electrodiagnostic features have not been fully characterized. Methods: We retrospectively reviewed medical records of the patients diagnosed with GBS and its variants following COVID-19 vaccination at four referral hospitals during the period of the mass vaccination program in South Korea (February to October 2021). Results: We identified 13 patients with GBS and variants post COVID-19 vaccination: AstraZeneca vaccine (Vaxzevria) in 8, and Pfizer-BioNTech vaccine (Comirnaty) in 5. The mean time interval from vaccination to symptom onset was 15.6 days (range 4-30 days). Electrodiagnostic classification was demyelinating in 7, axonal in 4 and normal in 2 cases. Clinical manifestations were diverse with varying severity: classical GBS in 8 cases, paraparetic variant in 3, Miller-Fisher syndrome in 1 and acute cervicobrachial weakness in 1. Four patients developed respiratory failure, and 2 of them showed treatment-related fluctuations. Conclusion: Our observations suggest that COVID-19 vaccines may be associated with GBS of distinctive clinical features characterized by severe quadriplegia, disproportionately frequent bilateral facial palsy or atypical incomplete variants. Continuous surveillance and further studies using robust study designs are warranted to fully assess the significance of the association.

Reply: To PMID 25440819.

Fluctuations of Northeast Arctic Cod Catches: A Review of Possible Sources

Psychiatric adverse events following COVID-19 vaccination: a population-based cohort study in Seoul, South Korea

Cardiac and Neurological Complications Post COVID-19 Vaccination: A Systematic Review of Case Reports and Case Series

Broad-spectrum of non-serious adverse events following COVID-19 vaccination: A population-based cohort study in Seoul, South Korea

Global and regional burden of vaccine‐associated facial paralysis, 1967–2023: Findings from the WHO international pharmacovigilance database

Risk of encephalitis and meningitis after COVID-19 vaccination in South Korea: a self-controlled case series analysis

COVID-19 vaccination and ocular adverse events: a self-controlled case series study from the entire South Korean population

Neonatal congestive heart failure as the presenting symptom of cerebral arteriovenous malformation.

Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection

COVID-19 vaccine safety: Background incidence rates of anaphylaxis, myocarditis, pericarditis, Guillain-Barré Syndrome, and mortality in South Korea using a nationwide population-based cohort study

Headache Triggered by Coronavirus Disease 2019 Vaccination Increases in Line with History of Allergic Disorders and Comorbidities Like Depression and Fibromyalgia: An Analysis of the US Vaccine Adverse Event Reporting System

Central Nervous System Demyelination Following COVID-19 mRNA-Based Vaccination: Two Case Reports and Literature Review

Neurological Events Following COVID-19 Vaccination: Does Ethnicity Matter?

Retinal Vascular Occlusions After COVID-19 Vaccination in South Korea: A Nation-Wide Population-Based Study

A further complication of informed consent.

Increased risk of functional neurological disorders following SARS‐CoV‐2 vaccination

Thromboembolism after coronavirus disease 2019 vaccination in atrial fibrillation/flutter: a self-controlled case series study

Incidence and clinical characteristics of adverse neurological events and stroke-like syndrome associated with immune stress-related response after COVID-19 vaccination in 2021 from Thailand

Vaccination and the risk of post-acute sequelae after COVID-19 In the Omicron-predominant period

Guillain-Barré Syndrome and Variants Following COVID-19 Vaccination: Report of 13 Cases